News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow by Adam Sheldon April 20, 2026April 22, 2026 Nexalis Therapeutics – formerly InhaleRx – has completed dosing in the first cohort of its Phase […]
Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent by Adam Sheldon February 2, 2026February 5, 2026
Elixinol records first underlying operating cash flow positive quarter by Adam Sheldon February 2, 2026February 3, 2026
InhaleRx locks in A$1m cap raise and reveals plans to rebrand by Adam Sheldon December 1, 2025February 21, 2026
Financial news in brief: Elixinol addresses funding concerns; Aurora growth helped by Australia; Avecho lifts cash, progresses trial; Cann receives NAB extension to finalise settlement; IRX reports lean quarter by Adam Sheldon November 4, 2025February 21, 2026
News in brief: Cann Group trading halt; Avecho raises $2.5m for CBD submission; IRX CEO takes shares over salary by Adam Sheldon October 23, 2025February 21, 2026
News in brief: Losses widen for Avecho and Elixinol; InhaleRx secures HREC approval; Zelira cuts deficit; Argent shifts from ‘non-core’ activities by Adam Sheldon August 29, 2025February 21, 2026
InhaleRx reports half-year loss but advances clinical trial plans by Martin Lane August 26, 2025August 28, 2025
